Literature DB >> 17259801

First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.

A Colao1, E Martino, P Cappabianca, R Cozzi, M Scanarini, E Ghigo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17259801     DOI： 10.1007/bf03349217

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  31 in total

Review 1.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

Authors:  John S Bevan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

Review 3.  Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

Authors:  J J Kopchick; C Parkinson; E C Stevens; P J Trainer
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

4.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Authors:  Shlomo Melmed; Richard Sternberg; David Cook; Anne Klibanski; Philippe Chanson; Vivien Bonert; Mary Lee Vance; David Rhew; David Kleinberg; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2005-04-12       Impact factor: 5.958

5.  Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years.

Authors:  G Minniti; D Traish; S Ashley; A Gonsalves; M Brada
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

6.  Effect of different dopaminergic agents in the treatment of acromegaly.

Authors:  A Colao; D Ferone; P Marzullo; A Di Sarno; G Cerbone; F Sarnacchiaro; S Cirillo; B Merola; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

7.  Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.

Authors:  Annamaria Colao; Roberto Attanasio; Rosario Pivonello; Paolo Cappabianca; Luigi M Cavallo; Giovanni Lasio; Alessandro Lodrini; Gaetano Lombardi; Renato Cozzi
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

8.  Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.

Authors:  Ariel L Barkan; Pia Burman; David R Clemmons; William M Drake; Robert F Gagel; Philip E Harris; Peter J Trainer; Aart Jan van der Lely; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2005-08-02       Impact factor: 5.958

9.  Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study.

Authors:  Roberto Attanasio; Paolo Epaminonda; Enrico Motti; Enrico Giugni; Laura Ventrella; Renato Cozzi; Mario Farabola; Paola Loli; Paolo Beck-Peccoz; Maura Arosio
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

10.  Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

Authors:  J Ayuk; R N Clayton; G Holder; M C Sheppard; P M Stewart; A S Bates
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958
View more
  18 in total

1.  Dose optimization of somatostatin analogues for acromegaly patients.

Authors:  A Colao; G Lombardi
Journal:  J Endocrinol Invest       Date:  2010-02       Impact factor: 4.256

Review 2.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

Review 3.  Somatostatin agonists for treatment of acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Mol Cell Endocrinol       Date:  2007-11-29       Impact factor: 4.102

4.  The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend?

Authors:  A Colao; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

Review 5.  Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

6.  Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance.

Authors:  F Bogazzi; M Lombardi; E Strata; G Aquaro; M Lombardi; C Urbani; V Di Bello; C Cosci; C Sardella; E Talini; E Martino
Journal:  J Endocrinol Invest       Date:  2010-02       Impact factor: 4.256

7.  Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study.

Authors:  Carla Giordano; Alessandro Ciresi; Marco Calogero Amato; Rosario Pivonello; Renata Simona Auriemma; Ludovica Francesca Stella Grasso; Aldo Galluzzo; Annamaria Colao
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

8.  Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients.

Authors:  V Gasco; G Beccuti; F Marotta; N Prencipe; M Maccario; J Janssen; A J van der Lely; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2011-05-31       Impact factor: 4.256

9.  Italian Society of Endocrinology Career Award Lecture: from somatostatin to…somatomedin.

Authors:  D Ferone
Journal:  J Endocrinol Invest       Date:  2012-08-29       Impact factor: 4.256

Review 10.  Medical therapy of pituitary adenomas: effects on tumor shrinkage.

Authors:  Annamaria Colao; Rosario Pivonello; Carolina Di Somma; Silvia Savastano; Ludovica F S Grasso; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.